Top Markets
#1 Black Phoenix Black Phoenix +734.10%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.73%
#3 THORChain THORChain +22.75%
#4 MiL.k Alliance MiL.k Alliance +19.00%
#5 Biconomy Biconomy +17.52%
#6 TENDIES TENDIES +17.07%
#7 THORChain Yield THORChain Yield +17.03%
#8 Gigachad Gigachad +14.96%
#9 Tutorial Tutorial +14.38%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +14.32%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Hybio Pharmaceutical Co., Ltd. Hybio Pharmaceutical Co., Ltd.

Hybio Pharmaceutical Co., Ltd.

300199
Classifica tra le azioni #5173
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Prezzo delle azioni
$3.33
Capitalizzazione di mercato
$2.95B
Variazione (1 giorno)
1.50%
Variazione (1 anno)
-8.64%
Paese
CN
Scambia Hybio Pharmaceutical Co., Ltd. (300199)

Categoria

Healthcare
Margine operativo per Hybio Pharmaceutical Co., Ltd. (300199)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Hybio Pharmaceutical Co., Ltd., il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per Hybio Pharmaceutical Co., Ltd. da 2026 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
Non abbastanza dati per le date fornite.
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00% -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00% -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00% -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00% -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
22.93% -
IN
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.